Home > Press Releases > Antifungal Drugs Market

Antifungal Drugs Market Likely to Surpass USD 22.1 Billion by 2035

Report Code: HC-42260  |  Published in: Sep 2025, By MarketGenics  |  Number of pages: 450
Get PDF
Buy

Global Antifungal Drugs Market Forecast 2035:

According to the report, the global antifungal drugs market is likely to grow from USD 14.3 Billion in 2025 to USD 22.1 Billion in 2035 at a highest CAGR of 4.0% during the time period. The antifungal drugs market is experiencing positive growth globally owing to the increasing number of infected patients especially among those who are immunocompromised such as those with HIV/AIDS, cancer or undergoing organ transplants. The rising numbers of opportunistic infections in the hospital environment, alongside the rising geriatric population, are generating a long-term need to seek out effective antifungal therapies. Extended-release oral and targeted intravenous antifungal agents are the technological improvements that can increase patient compliance and treatment efficacy.

Further, increased awareness on early diagnosis and early intervention due to the rising healthcare infrastructure in the emerging economies is increasing adoption rates. Resistant strains of fungi have also increased research and development efforts and drug companies have developed new antifungal molecules and combination regimens. Government projects to promote easy access to healthcare and reimbursement policies also help with market growth, and the wider availability of over-the-counter in some areas helps cover more patients.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Antifungal Drugs Market

One of the key drivers to the global antifungal drugs market is increasing prevalence of dermatophytid and systemic fungal infections. The rise of diseases like athlete-foot, candidiasis, invasive aspergillosis predominantly in immunocompromised and hospitalized humans, are also driving the demand of effective antifungal treatment, and this is driving up hospital and retail sales.

Treatment expenses and inaccessibility of modern antifungal drugs in poor countries limit market expansion. The high cost of branded medications and long-term regimens can also lead to a lack of compliance, which will decrease overall adoption and can limit infiltration in price-sensitive groups.

An opportunity of growth is the expansion of antifungal drugs in veterinary use. An increasing number of animals kept as pets and more cases of fungus in animals have driven pharmaceutical firms to develop novel antifungal preparations targeting the animal market, thus creating a new source of revenue.

Expansion of Global Antifungal Drugs Market

“Global Antifungal Drugs Market: Key Growth Drivers, Challenges, and Expansion Factors”

  • The market size of antifungal drugs is growing at an alarming rate across the world following the rise in the prevalence of fungal infections. The World Health Organization estimates that more than 300 million individuals across the globe are infected with severe cases of fungi each year, and immunocompromised individuals are the most vulnerable to this disease. Systemic antifungals, especially echinocandins and azoles are increasingly being demanded in hospitals and clinics to treat invasive infections like candidemia and aspergillosis. Drug manufacturers such as Pfizer and Gilead are working towards the development of new systemic antifungals to address this important healthcare requirement.
  • Market growth is being fueled by increasing awareness and early diagnosis programs. Healthcare organizations and governments are encouraging awareness and screening of fungal infections especially in areas where HIV/AIDS is in high prevalence. In the case of sub-Saharan Africa and southeast Asia, specifically, targeted awareness has resulted in an increased prescription of antifungal medicines, which stimulates market development in the developing areas.
  • The growth of the technological innovations and developments in formulations. Business enterprises are working on topical and oral antifungal agents that are more bioavailable, have fewer side effects, and are easy to take. As such, Pfizer Lamisil and Novartis Mycamine have better efficacy and adherence, and both have become more acceptable in developed and developing countries, increasing the overall market of antifungal drugs

Regional Analysis of Global Antifungal Drugs Market

  • The North American market is leading in terms of antifungal drugs because of well-developed healthcare systems, high incidence of fungal diseases in immunocompromised people, and the speed at which innovative antifungal treatment is embraced. The demand is further fuelled by increasing awareness on early diagnosis and treatment, sound healthcare support and reimbursement policies by the government, and a strong demand across hospitals and specialty clinics in the area.
  • The most growth is experienced in the Asian Pacific because there is increasing access to healthcare, increased incidence of fungal infections attributed to rising cases of diabetes and HIV, and increasing investment in pharmaceutical production. There is a tremendous market potential in both hospital and retail pharmacy sectors, as countries such as India, China and Japan are rapidly urbanizing, enhancing their diagnostic facilities and embracing the use of branded antifungal drugs.

Prominent players operating in the global antifungal drugs market are Amphastar Pharmaceuticals, Astellas Pharma Inc., Bayer AG, Biocon Ltd., Bristol Myers Squibb, Cipla Ltd., Dr. Reddy’s Laboratories, Eisai Co., Ltd., GSK (GlaxoSmithKline plc), Hikma Pharmaceuticals, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Mylan N.V. (now part of Viatris), Novartis International AG, Pfizer Inc., Roche Holding AG, Sandoz International GmbH (Novartis division), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and Other Key Players.

The global antifungal drugs market has been segmented as follows:

Global Antifungal Drugs Market Analysis, by Drug Class

  • Azoles
    • Fluconazole
    • Itraconazole
    • Voriconazole
    • Others
  • Echinocandins
    • Caspofungin
    • Micafungin
    • Others
  • Polyenes
    • Amphotericin B
    • Nystatin
    • Others
  • Allylamines
    • Terbinafine
    • Naftifine
    • Others
  • Others (e.g., Flucytosine, Griseofulvin)

Global Antifungal Drugs Market Analysis, by Infection Type/ Indication

  • Dermatophytosis
  • Aspergillosis
  • Candidiasis (oral, vaginal, invasive)
  • Mucormycosis
  • Cryptococcal Meningitis
  • Others (e.g., onychomycosis, tinea infections)

Global Antifungal Drugs Market Analysis, by Dosage Form

  • Oral Tablets & Capsules
  • Topical Creams, Ointments, and Lotions
  • Parenteral/Injectable
  • Powders & Sprays
  • Suppositories
  • Others

Global Antifungal Drugs Market Analysis, by Patient Type

  • Immunocompromised Patients
  • HIV/AIDS
  • Cancer
  • Organ Transplant
  • Others
  • General Population (e.g., superficial fungal infections)

Global Antifungal Drugs Market Analysis, by End User

  • Hospitals
  • Retail Pharmacies
  • Specialty Clinics
  • Online Pharmacies
  • Homecare Settings
  • Others

Global Antifungal Drugs Market Analysis, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Wholesalers/ Distributors

Global Antifungal Drugs Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America
 

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Antifungal Drugs Market Outlook
      • 2.1.1. Antifungal Drugs Market Size (Value - US$ Billion), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End Use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2025-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Overview, 2025
      • 3.1.1. Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising prevalence of fungal infections, especially among immunocompromised and hospital populations
        • 4.1.1.2. Advancements in antifungal drug development, including novel compounds and delivery systems.
        • 4.1.1.3. Growing awareness and improved diagnostics for fungal diseases among healthcare providers and patients
      • 4.1.2. Restraints
        • 4.1.2.1. High cost of antifungal therapies and limited reimbursement/access, particularly in low- and middle-income regions.
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
      • 4.4.1. Raw Material Suppliers
      • 4.4.2. Formulation Development and Drug Producers
      • 4.4.3. Healthcare Providers
      • 4.4.4. Wholesalers/ Retailers
      • 4.4.5. End User/ Customer
    • 4.5. Cost Structure Analysis
      • 4.5.1. Parameter’s Share for Cost Associated
      • 4.5.2. COGP vs COGS
      • 4.5.3. Profit Margin Analysis
    • 4.6. Pricing Analysis
      • 4.6.1. Regional Pricing Analysis
      • 4.6.2. Segmental Pricing Trends
      • 4.6.3. Factors Influencing Pricing
    • 4.7. Porter’s Five Forces Analysis
    • 4.8. PESTEL Analysis
    • 4.9. Global Antifungal Drugs Market Demand
      • 4.9.1. Historical Market Size - in Value (Value - US$ Billion), 2021-2024
      • 4.9.2. Current and Future Market Size - in Value (Value - US$ Billion), 2025–2035
        • 4.9.2.1. Y-o-Y Growth Trends
        • 4.9.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Antifungal Drugs Market Analysis, by Drug Class
    • 6.1. Key Segment Analysis
    • 6.2. Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, by Drug Class, 2021-2035
      • 6.2.1. Azoles
        • 6.2.1.1. Fluconazole
        • 6.2.1.2. Itraconazole
        • 6.2.1.3. Voriconazole
        • 6.2.1.4. Others
      • 6.2.2. Echinocandins
        • 6.2.2.1. Caspofungin
        • 6.2.2.2. Micafungin
        • 6.2.2.3. Others
      • 6.2.3. Polyenes
        • 6.2.3.1. Amphotericin B
        • 6.2.3.2. Nystatin
        • 6.2.3.3. Others
      • 6.2.4. Allylamines
        • 6.2.4.1. Terbinafine
        • 6.2.4.2. Naftifine
        • 6.2.4.3. Others
      • 6.2.5. Others (e.g., Flucytosine, Griseofulvin)
  • 7. Global Antifungal Drugs Market Analysis, by Infection Type/ Indication
    • 7.1. Key Segment Analysis
    • 7.2. Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, by Infection Type/ Indication, 2021-2035
      • 7.2.1. Dermatophytosis
      • 7.2.2. Aspergillosis
      • 7.2.3. Candidiasis (oral, vaginal, invasive)
      • 7.2.4. Mucormycosis
      • 7.2.5. Cryptococcal Meningitis
      • 7.2.6. Others (e.g., onychomycosis, tinea infections)
  • 8. Global Antifungal Drugs Market Analysis, by Dosage Form
    • 8.1. Key Segment Analysis
    • 8.2. Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, by Dosage Form, 2021-2035
      • 8.2.1. Oral Tablets & Capsules
      • 8.2.2. Topical Creams, Ointments, and Lotions
      • 8.2.3. Parenteral/Injectable
      • 8.2.4. Powders & Sprays
      • 8.2.5. Suppositories
      • 8.2.6. Others
  • 9. Global Antifungal Drugs Market Analysis, by Patient Type
    • 9.1. Key Segment Analysis
    • 9.2. Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, by Patient Type, 2021-2035
      • 9.2.1. Immunocompromised Patients
        • 9.2.1.1. HIV/AIDS
        • 9.2.1.2. Cancer
        • 9.2.1.3. Organ Transplant
        • 9.2.1.4. Others
      • 9.2.2. General Population (e.g., superficial fungal infections)
  • 10. Global Antifungal Drugs Market Analysis, by End User
    • 10.1. Key Segment Analysis
    • 10.2. Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, by End User, 2021-2035
      • 10.2.1. Hospitals
      • 10.2.2. Retail Pharmacies
      • 10.2.3. Specialty Clinics
      • 10.2.4. Online Pharmacies
      • 10.2.5. Homecare Settings
      • 10.2.6. Others
  • 11. Global Antifungal Drugs Market Analysis, by Distribution Channel
    • 11.1. Key Segment Analysis
    • 11.2. Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, by Distribution Channel, 2021-2035
      • 11.2.1. Hospital Pharmacies
      • 11.2.2. Retail Pharmacies
      • 11.2.3. Online Pharmacies
      • 11.2.4. Drug Wholesalers/ Distributors
  • 12. Global Antifungal Drugs Market Analysis and Forecasts, by Region
    • 12.1. Key Findings
    • 12.2. Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, by Region, 2021-2035
      • 12.2.1. North America
      • 12.2.2. Europe
      • 12.2.3. Asia Pacific
      • 12.2.4. Middle East
      • 12.2.5. Africa
      • 12.2.6. South America
  • 13. North America Antifungal Drugs Market Analysis
    • 13.1. Key Segment Analysis
    • 13.2. Regional Snapshot
    • 13.3. North America Antifungal Drugs Market Size Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 13.3.1. Drug Class
      • 13.3.2. Infection Type/ Indication
      • 13.3.3. Dosage Form
      • 13.3.4. Patient Type
      • 13.3.5. End User
      • 13.3.6. Distribution Channel
      • 13.3.7. Country
        • 13.3.7.1. USA
        • 13.3.7.2. Canada
        • 13.3.7.3. Mexico
    • 13.4. USA Antifungal Drugs Market
      • 13.4.1. Country Segmental Analysis
      • 13.4.2. Drug Class
      • 13.4.3. Infection Type/ Indication
      • 13.4.4. Dosage Form
      • 13.4.5. Patient Type
      • 13.4.6. End User
      • 13.4.7. Distribution Channel
    • 13.5. Canada Antifungal Drugs Market
      • 13.5.1. Country Segmental Analysis
      • 13.5.2. Drug Class
      • 13.5.3. Infection Type/ Indication
      • 13.5.4. Dosage Form
      • 13.5.5. Patient Type
      • 13.5.6. End User
      • 13.5.7. Distribution Channel
    • 13.6. Mexico Antifungal Drugs Market
      • 13.6.1. Country Segmental Analysis
      • 13.6.2. Drug Class
      • 13.6.3. Infection Type/ Indication
      • 13.6.4. Dosage Form
      • 13.6.5. Patient Type
      • 13.6.6. End User
      • 13.6.7. Distribution Channel
  • 14. Europe Antifungal Drugs Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. Europe Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Drug Class
      • 14.3.2. Infection Type/ Indication
      • 14.3.3. Dosage Form
      • 14.3.4. Patient Type
      • 14.3.5. End User
      • 14.3.6. Distribution Channel
      • 14.3.7. Country
        • 14.3.7.1. Germany
        • 14.3.7.2. United Kingdom
        • 14.3.7.3. France
        • 14.3.7.4. Italy
        • 14.3.7.5. Spain
        • 14.3.7.6. Netherlands
        • 14.3.7.7. Nordic Countries
        • 14.3.7.8. Poland
        • 14.3.7.9. Russia & CIS
        • 14.3.7.10. Rest of Europe
    • 14.4. Germany Antifungal Drugs Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Drug Class
      • 14.4.3. Infection Type/ Indication
      • 14.4.4. Dosage Form
      • 14.4.5. Patient Type
      • 14.4.6. End User
      • 14.4.7. Distribution Channel
    • 14.5. United Kingdom Antifungal Drugs Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Drug Class
      • 14.5.3. Infection Type/ Indication
      • 14.5.4. Dosage Form
      • 14.5.5. Patient Type
      • 14.5.6. End User
      • 14.5.7. Distribution Channel
    • 14.6. France Antifungal Drugs Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Drug Class
      • 14.6.3. Infection Type/ Indication
      • 14.6.4. Dosage Form
      • 14.6.5. Patient Type
      • 14.6.6. End User
      • 14.6.7. Distribution Channel
    • 14.7. Italy Antifungal Drugs Market
      • 14.7.1. Country Segmental Analysis
      • 14.7.2. Drug Class
      • 14.7.3. Infection Type/ Indication
      • 14.7.4. Dosage Form
      • 14.7.5. Patient Type
      • 14.7.6. End User
      • 14.7.7. Distribution Channel
    • 14.8. Spain Antifungal Drugs Market
      • 14.8.1. Country Segmental Analysis
      • 14.8.2. Drug Class
      • 14.8.3. Infection Type/ Indication
      • 14.8.4. Dosage Form
      • 14.8.5. Patient Type
      • 14.8.6. End User
      • 14.8.7. Distribution Channel
    • 14.9. Netherlands Antifungal Drugs Market
      • 14.9.1. Country Segmental Analysis
      • 14.9.2. Drug Class
      • 14.9.3. Infection Type/ Indication
      • 14.9.4. Dosage Form
      • 14.9.5. Patient Type
      • 14.9.6. End User
      • 14.9.7. Distribution Channel
    • 14.10. Nordic Countries Antifungal Drugs Market
      • 14.10.1. Country Segmental Analysis
      • 14.10.2. Drug Class
      • 14.10.3. Infection Type/ Indication
      • 14.10.4. Dosage Form
      • 14.10.5. Patient Type
      • 14.10.6. End User
      • 14.10.7. Distribution Channel
    • 14.11. Poland Antifungal Drugs Market
      • 14.11.1. Country Segmental Analysis
      • 14.11.2. Drug Class
      • 14.11.3. Infection Type/ Indication
      • 14.11.4. Dosage Form
      • 14.11.5. Patient Type
      • 14.11.6. End User
      • 14.11.7. Distribution Channel
    • 14.12. Russia & CIS Antifungal Drugs Market
      • 14.12.1. Country Segmental Analysis
      • 14.12.2. Drug Class
      • 14.12.3. Infection Type/ Indication
      • 14.12.4. Dosage Form
      • 14.12.5. Patient Type
      • 14.12.6. End User
      • 14.12.7. Distribution Channel
    • 14.13. Rest of Europe Antifungal Drugs Market
      • 14.13.1. Country Segmental Analysis
      • 14.13.2. Drug Class
      • 14.13.3. Infection Type/ Indication
      • 14.13.4. Dosage Form
      • 14.13.5. Patient Type
      • 14.13.6. End User
      • 14.13.7. Distribution Channel
  • 15. Asia Pacific Antifungal Drugs Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. East Asia Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Drug Class
      • 15.3.2. Infection Type/ Indication
      • 15.3.3. Dosage Form
      • 15.3.4. Patient Type
      • 15.3.5. End User
      • 15.3.6. Distribution Channel
      • 15.3.7. Country
        • 15.3.7.1. China
        • 15.3.7.2. India
        • 15.3.7.3. Japan
        • 15.3.7.4. South Korea
        • 15.3.7.5. Australia and New Zealand
        • 15.3.7.6. Indonesia
        • 15.3.7.7. Malaysia
        • 15.3.7.8. Thailand
        • 15.3.7.9. Vietnam
        • 15.3.7.10. Rest of Asia Pacific
    • 15.4. China Antifungal Drugs Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Drug Class
      • 15.4.3. Infection Type/ Indication
      • 15.4.4. Dosage Form
      • 15.4.5. Patient Type
      • 15.4.6. End User
      • 15.4.7. Distribution Channel
    • 15.5. India Antifungal Drugs Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Drug Class
      • 15.5.3. Infection Type/ Indication
      • 15.5.4. Dosage Form
      • 15.5.5. Patient Type
      • 15.5.6. End User
      • 15.5.7. Distribution Channel
    • 15.6. Japan Antifungal Drugs Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Drug Class
      • 15.6.3. Infection Type/ Indication
      • 15.6.4. Dosage Form
      • 15.6.5. Patient Type
      • 15.6.6. End User
      • 15.6.7. Distribution Channel
    • 15.7. South Korea Antifungal Drugs Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Drug Class
      • 15.7.3. Infection Type/ Indication
      • 15.7.4. Dosage Form
      • 15.7.5. Patient Type
      • 15.7.6. End User
      • 15.7.7. Distribution Channel
    • 15.8. Australia and New Zealand Antifungal Drugs Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Drug Class
      • 15.8.3. Infection Type/ Indication
      • 15.8.4. Dosage Form
      • 15.8.5. Patient Type
      • 15.8.6. End User
      • 15.8.7. Distribution Channel
    • 15.9. Indonesia Antifungal Drugs Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Drug Class
      • 15.9.3. Infection Type/ Indication
      • 15.9.4. Dosage Form
      • 15.9.5. Patient Type
      • 15.9.6. End User
      • 15.9.7. Distribution Channel
    • 15.10. Malaysia Antifungal Drugs Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Drug Class
      • 15.10.3. Infection Type/ Indication
      • 15.10.4. Dosage Form
      • 15.10.5. Patient Type
      • 15.10.6. End User
      • 15.10.7. Distribution Channel
    • 15.11. Thailand Antifungal Drugs Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Drug Class
      • 15.11.3. Infection Type/ Indication
      • 15.11.4. Dosage Form
      • 15.11.5. Patient Type
      • 15.11.6. End User
      • 15.11.7. Distribution Channel
    • 15.12. Vietnam Antifungal Drugs Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Drug Class
      • 15.12.3. Infection Type/ Indication
      • 15.12.4. Dosage Form
      • 15.12.5. Patient Type
      • 15.12.6. End User
      • 15.12.7. Distribution Channel
    • 15.13. Rest of Asia Pacific Antifungal Drugs Market
      • 15.13.1. Country Segmental Analysis
      • 15.13.2. Drug Class
      • 15.13.3. Infection Type/ Indication
      • 15.13.4. Dosage Form
      • 15.13.5. Patient Type
      • 15.13.6. End User
      • 15.13.7. Distribution Channel
  • 16. Middle East Antifungal Drugs Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Middle East Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Drug Class
      • 16.3.2. Infection Type/ Indication
      • 16.3.3. Dosage Form
      • 16.3.4. Patient Type
      • 16.3.5. End User
      • 16.3.6. Distribution Channel
      • 16.3.7. Country
        • 16.3.7.1. Turkey
        • 16.3.7.2. UAE
        • 16.3.7.3. Saudi Arabia
        • 16.3.7.4. Israel
        • 16.3.7.5. Rest of Middle East
    • 16.4. Turkey Antifungal Drugs Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Drug Class
      • 16.4.3. Infection Type/ Indication
      • 16.4.4. Dosage Form
      • 16.4.5. Patient Type
      • 16.4.6. End User
      • 16.4.7. Distribution Channel
    • 16.5. UAE Antifungal Drugs Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Drug Class
      • 16.5.3. Infection Type/ Indication
      • 16.5.4. Dosage Form
      • 16.5.5. Patient Type
      • 16.5.6. End User
      • 16.5.7. Distribution Channel
    • 16.6. Saudi Arabia Antifungal Drugs Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Drug Class
      • 16.6.3. Infection Type/ Indication
      • 16.6.4. Dosage Form
      • 16.6.5. Patient Type
      • 16.6.6. End User
      • 16.6.7. Distribution Channel
    • 16.7. Israel Antifungal Drugs Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Drug Class
      • 16.7.3. Infection Type/ Indication
      • 16.7.4. Dosage Form
      • 16.7.5. Patient Type
      • 16.7.6. End User
      • 16.7.7. Distribution Channel
    • 16.8. Rest of Middle East Antifungal Drugs Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Drug Class
      • 16.8.3. Infection Type/ Indication
      • 16.8.4. Dosage Form
      • 16.8.5. Patient Type
      • 16.8.6. End User
      • 16.8.7. Distribution Channel
  • 17. Africa Antifungal Drugs Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Africa Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Drug Class
      • 17.3.2. Infection Type/ Indication
      • 17.3.3. Dosage Form
      • 17.3.4. Patient Type
      • 17.3.5. End User
      • 17.3.6. Distribution Channel
      • 17.3.7. Country
        • 17.3.7.1. South Africa
        • 17.3.7.2. Egypt
        • 17.3.7.3. Nigeria
        • 17.3.7.4. Algeria
        • 17.3.7.5. Rest of Africa
    • 17.4. South Africa Antifungal Drugs Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Drug Class
      • 17.4.3. Infection Type/ Indication
      • 17.4.4. Dosage Form
      • 17.4.5. Patient Type
      • 17.4.6. End User
      • 17.4.7. Distribution Channel
    • 17.5. Egypt Antifungal Drugs Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Drug Class
      • 17.5.3. Infection Type/ Indication
      • 17.5.4. Dosage Form
      • 17.5.5. Patient Type
      • 17.5.6. End User
      • 17.5.7. Distribution Channel
    • 17.6. Nigeria Antifungal Drugs Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Drug Class
      • 17.6.3. Infection Type/ Indication
      • 17.6.4. Dosage Form
      • 17.6.5. Patient Type
      • 17.6.6. End User
      • 17.6.7. Distribution Channel
    • 17.7. Algeria Antifungal Drugs Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Drug Class
      • 17.7.3. Infection Type/ Indication
      • 17.7.4. Dosage Form
      • 17.7.5. Patient Type
      • 17.7.6. End User
      • 17.7.7. Distribution Channel
    • 17.8. Rest of Africa Antifungal Drugs Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Drug Class
      • 17.8.3. Infection Type/ Indication
      • 17.8.4. Dosage Form
      • 17.8.5. Patient Type
      • 17.8.6. End User
      • 17.8.7. Distribution Channel
  • 18. South America Antifungal Drugs Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Central and South Africa Antifungal Drugs Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Drug Class
      • 18.3.2. Infection Type/ Indication
      • 18.3.3. Dosage Form
      • 18.3.4. Patient Type
      • 18.3.5. End User
      • 18.3.6. Distribution Channel
      • 18.3.7. Country
        • 18.3.7.1. Brazil
        • 18.3.7.2. Argentina
        • 18.3.7.3. Rest of South America
    • 18.4. Brazil Antifungal Drugs Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Drug Class
      • 18.4.3. Infection Type/ Indication
      • 18.4.4. Dosage Form
      • 18.4.5. Patient Type
      • 18.4.6. End User
      • 18.4.7. Distribution Channel
    • 18.5. Argentina Antifungal Drugs Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Drug Class
      • 18.5.3. Infection Type/ Indication
      • 18.5.4. Dosage Form
      • 18.5.5. Patient Type
      • 18.5.6. End User
      • 18.5.7. Distribution Channel
    • 18.6. Rest of South America Antifungal Drugs Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Drug Class
      • 18.6.3. Infection Type/ Indication
      • 18.6.4. Dosage Form
      • 18.6.5. Patient Type
      • 18.6.6. End User
      • 18.6.7. Distribution Channel
  • 19. Key Players/ Company Profile
    • 19.1. Amphastar Pharmaceuticals
      • 19.1.1. Company Details/ Overview
      • 19.1.2. Company Financials
      • 19.1.3. Key Customers and Competitors
      • 19.1.4. Business/ Industry Portfolio
      • 19.1.5. Product Portfolio/ Specification Details
      • 19.1.6. Pricing Data
      • 19.1.7. Strategic Overview
      • 19.1.8. Recent Developments
    • 19.2. Astellas Pharma Inc.
    • 19.3. Bayer AG
    • 19.4. Biocon Ltd.
    • 19.5. Bristol Myers Squibb
    • 19.6. Cipla Ltd.
    • 19.7. Dr. Reddy’s Laboratories
    • 19.8. Eisai Co., Ltd.
    • 19.9. GSK (GlaxoSmithKline plc)
    • 19.10. Hikma Pharmaceuticals
    • 19.11. Johnson & Johnson
    • 19.12. Lupin Limited
    • 19.13. Merck & Co., Inc.
    • 19.14. Mylan N.V. (now part of Viatris)
    • 19.15. Novartis International AG
    • 19.16. Pfizer Inc.
    • 19.17. Roche Holding AG
    • 19.18. Sandoz International GmbH (Novartis division)
    • 19.19. Sun Pharmaceutical Industries Ltd.
    • 19.20. Teva Pharmaceutical Industries Ltd.
    • 19.21. Other Key Players

 

Note* - This is just tentative list of players. While providing the report, we will cover a greater number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150.00
USD 5950.00
USD 7750.00
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation